https://www.vergentbio.com/press-releases/vergent-bioscience-initiates-phase-3-visualize-2-pivotal-study-of-abenacianine-(vgt-309)-for-tumor-visualization-during-lung-cancer-surgery 2026-03-17 https://www.vergentbio.com/press-releases/vergent-bioscience-to-present-data-on-abenacianine-for-injection-(vgt-309)-at-2025-american-society-of-clinical-oncology-(asco)-annual-meeting 2025-05-22 https://www.vergentbio.com/press-releases/vergent-bioscience-presents-phase-2b-visualize-results-demonstrating-abenacianine-for-injection-(vgt-309)-with-intraoperative-molecular-imaging-improved-tumor-visualization-during-lung-surgery 2025-05-22 https://www.vergentbio.com/press-releases/vergent-bioscience-receives-fda-fast-track-designation-for-abenacianine-for-injection--(vgt-309)-to-help-surgeons-visualize-tumors-in-the-lung-during-surgery- 2025-01-07 https://www.vergentbio.com/press-releases/vergent-bioscience-secures-%2421.5-million-series-b-financing-to-advance-clinical-development-of-tumor-targeted-fluorescent-imaging-agent-vgt-309 2024-12-03 https://www.vergentbio.com/press-releases/vergent-bioscience-awarded-national-cancer-institute-phase-2-grant-to-advance-clinical-development-of-vgt-309-in-lung-cancer 2024-12-03 https://www.vergentbio.com/press-releases/vergent-bioscience-to-present-phase-2-clinical-data-for-vgt-309-at-iaslc-2023-world-conference-on-lung-cancer 2024-12-03 https://www.vergentbio.com/press-releases/phase-2-data-demonstrate-potential-of-vergent-biosciences%E2%80%99-tumor-targeted-fluorescent-imaging-agent-to-improve-success-of-lung-cancer-surgeries 2024-12-03 https://www.vergentbio.com/press-releases/vergent-bioscience-initiates-phase-2%2C-multi-center-visualize-study-evaluating-efficacy-of-tumor-targeted-fluorescent-imaging-agent-vgt-309-in-lung-cancer-surgeries 2024-12-03 https://www.vergentbio.com/press-releases/vergent-bioscience-to-present-new-efficacy-results-from-phase-2-clinical-trial-of-vgt-309-at-annual-meeting-of-the-society-of-thoracic-surgeons 2024-12-03 https://www.vergentbio.com/press-releases/vergent-bioscience-presents-phase-2-data-showing-vgt-309-visualizes-tumors-in-the-lung-during-surgery 2024-12-03 https://www.vergentbio.com/press-releases/vergent-bioscience-data-published-in-the-annals-of-thoracic-surgery-demonstrate-vgt-309-may-help-surgeons-visualize-tumor-tissue-in-the-lung-during-surgery 2024-12-03 https://www.vergentbio.com/press-releases/vergent-bioscience-completes-enrollment-in-phase-2-visualize-trial-evaluating-potential-of-abenacianine-for-injection-(vgt-309)-to-improve-tumor-visualization-during-cancer-surgery 2024-12-03